IRB #

STUDY00019296

Title

A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

Principal Investigator

Adel Kardosh

Study Purpose

To compare the good and bad affects of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in participants with advanced colorectal cancer.

Medical Condition(s)

colorectal cancer

Eligibility Criteria

- Colorectal adenocarcinoma verified by biopsy.
- Availability of biopsy material, from the primary tumor or metastasis, allowing for analysis of tumor gene expression.
- Life expectancy of more than 4 months.
- Malignant tumors other than colorectal adenocarcinomas (current or within the previous five years), with the exception for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix.
- Confirmation of progressive disease within 6 months after completion of prior anti-cancer treatment.
- Indication for any metastatic Colo-rectal Cancer (mCRC) surgery or anti-cancer treatment other than study treatment.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Up to 5 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Isofol Medical AB

Recruitment End

12/01/2024

Compensation Provided

No


Go Back